According to a study published online November 4, 2019, COVID-19 has no long-term impact on the course of inflammatory bowel disease (IBD). Therapeutic Advances in Gastroenterology.
Simon J. Hong, MD, from NYU Langone Health in New York City, and colleagues evaluated the impact of COVID-19 on long-term outcomes of IBD. The analysis included 251 cases (45 percent ulcerative colitis; 55% of Crohn’s disease) and 251 controls, with a mean follow-up of 394 days.
The researchers found that the primary composite outcome of IBD-related hospitalization or surgery occurred in 29 cases (12%) compared with 38 controls (15%). COVID-19 was not associated with an increased risk of adverse IBD outcomes (adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.44 to 1.42). There were also no significant differences seen in adverse IBD outcomes based on COVID-19 severity (adjusted hazard ratio). [95 percent confidence intervals]2.43 [1.00 to 5.86] and 0.68 [0.38 to 1.23] for severe COVID-19 and mild to moderate COVID-19 respectively).
The authors write: “In this multicenter study, COVID-19 did not alter the long-term course of IBD; however, severe COVID-19 may herald a worse course and prognosis of IBD.” “Risk reduction and vaccination remain important strategies in the care of IBD patients during the ongoing COVID-19 pandemic.”
Some authors disclose financial relationships with pharmaceutical industry.
Summary/Full Text
Copyright © 2022 health day. Copyright Registered.
quote: COVID-19 was not associated with worse inflammatory bowel disease outcomes (2022, November 18) retrieved November 20, 2022 from https://medicalxpress.com/news/2022-11-covid- worse- Inflammatory-enteritis-disease.html
This document is the subject for the collection of authors. Other than any fair dealing for private learning or research purposes, no part may be reproduced without written permission. The content provided is for informational purposes only.
